Instrument Inactif

Communiqués Aviragen Therapeutics Inc Nasdaq

Actions

US0906941002

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

06/07	Vaxart publie les données préliminaires de sécurité à 12 mois de la cohorte sentinelle de 400 participants de l'essai clinique de phase 2b de son vaccin oral contre la Covid-19	CI
01/07	Vaxart, Inc. annonce des changements au sein de son conseil d'administration et de ses comités	CI

Communiqués

06/07	Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine	AQ
01/07	Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements	AQ
26/06	Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY	AQ
25/06	Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial	AQ
16/06	Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting	AQ
15/06	Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum	AQ
09/06	Vaxart to Participate in BTIG Infectious Disease Day 2026	AQ
08/06	Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY	AQ
01/06	Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders	AQ
19/05	Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders	AQ
08/05	Vaxart : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results	AQ
01/05	Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET	AQ
23/04	Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors	AQ
17/04	Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital	AQ
13/03	Vaxart : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)	PU
12/03	Vaxart Provides Business Update and Reports Full Year 2025 Financial Results	AQ
03/03	Vaxart to Host Upcoming Conference Calls	AQ
18/02	Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026	AQ
15/01	Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants	AQ
08/01	Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026	AQ
13/11	Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results	AQ
07/11	Vaxart to Host Upcoming Conference Calls	AQ
05/11	Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program	PR
05/11	Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program	PR